Entrovas Tablet 97 mg+103 mg contains a combination of Sacubitril and Valsartan, an advanced treatment used for managing chronic heart failure with reduced ejection fraction (HFrEF). This combination medicine belongs to a class known as angiotensin receptor neprilysin inhibitors (ARNIs) and is designed to improve heart function, relieve symptoms, and reduce the risk of hospitalization and cardiovascular death in patients with heart failure.

Heart failure is a long-term condition in which the heart cannot pump blood efficiently to meet the body’s needs. This can cause symptoms such as shortness of breath, fatigue, swelling of the legs or ankles, and reduced physical activity tolerance. Entrovas Tablet helps the heart pump blood more effectively by relaxing blood vessels, lowering blood pressure, and reducing the strain on the heart.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each tablet contains:

• Sacubitril 97 mg

• Valsartan 103 mg

Mechanism of Action

Entrovas Tablet works through the combined actions of its two active ingredients:

Sacubitril
Sacubitril is a neprilysin inhibitor that blocks the enzyme neprilysin responsible for breaking down beneficial peptides in the body. By inhibiting this enzyme, Sacubitril increases the levels of natriuretic peptides, which help:

• Relax and widen blood vessels

• Reduce blood pressure

• Increase excretion of sodium and water

• Decrease the workload on the heart

Valsartan
Valsartan is an angiotensin II receptor blocker (ARB) that prevents the effects of angiotensin II, a hormone that causes blood vessels to constrict. By blocking this hormone, Valsartan helps:

• Dilate blood vessels

• Lower blood pressure

• Improve blood flow

• Reduce stress on the heart

Together, these two medicines work synergistically to improve heart efficiency and reduce the progression of heart failure.

Indications

Entrovas Tablet 97 mg+103 mg is indicated for:

• Chronic heart failure with reduced ejection fraction (HFrEF)

• Reducing the risk of cardiovascular death in heart failure patients

• Lowering the risk of hospitalization due to worsening heart failure

• Improving symptoms such as breathlessness, fatigue, and swelling

This higher strength is typically used as a maintenance dose in patients who have already been stabilized on lower doses of Sacubitril/Valsartan.

Dosage and Administration

Dosage should be determined by a physician based on the patient’s medical condition and response to treatment.

General guidelines include:

• Usually one tablet twice daily

• Can be taken with or without food

• Swallow the tablet whole with a glass of water

• If switching from an ACE inhibitor, a 36-hour washout period is required before starting Entrovas

Regular monitoring of blood pressure, kidney function, and potassium levels is recommended during treatment.

Precautions

Before taking Entrovas Tablet, inform your doctor if you:

• Have kidney disease or liver impairment

• Have a history of angioedema

• Have low blood pressure

• Are pregnant or planning pregnancy

• Are taking potassium supplements, ACE inhibitors, or other blood pressure medicines

This medication should not be used during pregnancy due to potential harm to the unborn baby.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Like all medications, Entrovas Tablet may cause side effects in some individuals.

Common side effects include:

• Low blood pressure (hypotension)

• Dizziness or lightheadedness

• Elevated potassium levels

• Decreased kidney function

Less common but serious side effects:

• Angioedema (swelling of face, lips, or throat)

• Severe hypotension

• Kidney impairment

If severe or unusual symptoms occur, immediate medical attention should be sought.

Storage

• Store below 25°C in a cool and dry place

• Protect from moisture and direct sunlight

• Keep out of reach of children

Entrovas Tablet 97 mg+103 mg provides effective and advanced therapy for chronic heart failure, helping improve heart function, reduce symptoms, and lower the risk of serious cardiovascular complications.